Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial

被引:33
|
作者
Daneshi-Maskooni, Milad [1 ,2 ]
Keshavarz, Seyed Ali [3 ]
Qorbani, Mostafa [4 ]
Mansouri, Siavash [5 ]
Alavian, Seyed Moayed [6 ]
Badri-Fariman, Mahtab [1 ]
Jazayeri-Tehrani, Seyed Ali [3 ]
Sotoudeh, Gity [1 ]
机构
[1] Univ Tehran Med Sci, Sch Nutr Sci & Dietet, Dept Community Nutr, Tehran, Iran
[2] Jiroft Univ Med Sci, Sch Med, Kerman, Iran
[3] Univ Tehran Med Sci, Sch Nutr Sci & Dietet, Dept Clin Nutr, Tehran, Iran
[4] Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, Iran
[5] Natl Iranian Oil Co NIOC, Gastroenterohepatol Dept, Cent Hosp, Tehran, Iran
[6] Baqiyatallah Univ Med Sci, Baqiyatallah Res Ctr Gastroenterol & Liver Dis BR, Tehran, Iran
来源
关键词
Non-alcoholic fatty liver disease; Green cardamom; Overweight or obesity; Irisin; Glucose indices; Lipids; NF-KAPPA-B; ELETTARIA-CARDAMOMUM; HEPATIC STEATOSIS; BLOOD-PRESSURE; GINGER; NAFLD; DIET; METAANALYSIS; CONSUMPTION; PREVALENCE;
D O I
10.1186/s12906-019-2465-0
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
BackgroundDespite the reported health effects of cardamom on dyslipidemia, hepatomegaly, and fasting hyperglycemia, no human research has studied its potency in non-alcoholic fatty liver disease (NAFLD) as the hepatic part of metabolic syndrome. Our aim was determining the effects of green cardamom (GC) on serum glucose indices, lipids, and irisin level among overweight or obese NAFLD patients.MethodsThe place of participant recruitment was the polyclinic of the National Iranian Oil Company (NIOC) central hospital in Tehran. Based on the ultrasonography and eligibility criteria, 87 participants were randomly divided into two groups as cardamom (n=43) or placebo (n=44). The supplementation was two 500mg capsules 3 times/day with meals for 3months. Serum irisin, fasting blood sugar (FBS), insulin (FBI), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c) were measured. Quantitative insulin sensitivity check index (QUICKI) and homeostasis model assessment-insulin resistance (HOMA-IR) were also calculated.ResultsIn comparison with placebo, GC significantly increased irisin, HDL-c, and QUICKI and decreased FBI, TG, LDL-c, HOMA-IR, and the grade of fatty liver (P<0.05). After adjustment for confounders, the changes were similar (P<0.05) with an exception for LDL-c which had a trend (P=0.07). The differences in FBS, TC, and body mass index (BMI) were not significant (P>0.05).ConclusionGC supplement improved the grade of fatty liver, serum glucose indices, lipids, and irisin level among overweight or obese NAFLD patients. The changes in these biomarkers may yield beneficial effects on NAFLD. Further trials on the efficacy of GC for clinical practice are suggested.Trial registrationIranian Registry of Clinical Trials, IRCT2015121317254N4. Registered 27/12/2015,
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial
    Milad Daneshi-Maskooni
    Seyed Ali Keshavarz
    Mostafa Qorbani
    Siavash Mansouri
    Seyed Moayed Alavian
    Mahtab Badri-Fariman
    Seyed Ali Jazayeri-Tehrani
    Gity Sotoudeh
    [J]. BMC Complementary and Alternative Medicine, 19
  • [2] Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial
    Daneshi-Maskooni, Milad
    Keshavarz, Seyed Ali
    Qorbani, Mostafa
    Mansouri, Siavash
    Alavian, Seyed Moayed
    Badri-Fariman, Mahtab
    Jazayeri-Tehrani, Seyed Ali
    Sotoudeh, Gity
    [J]. NUTRITION & METABOLISM, 2018, 15
  • [3] Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial
    Milad Daneshi-Maskooni
    Seyed Ali Keshavarz
    Mostafa Qorbani
    Siavash Mansouri
    Seyed Moayed Alavian
    Mahtab Badri-Fariman
    Seyed Ali Jazayeri-Tehrani
    Gity Sotoudeh
    [J]. Nutrition & Metabolism, 15
  • [4] Quercetin supplementation in non-alcoholic fatty liver disease A randomized, double-blind, placebo-controlled clinical trial
    Hosseinikia, Mahboobe
    Oubari, Farhad
    Hosseinkia, Roghaye
    Tabeshfar, Zibaneh
    Salehi, Mohammad Gharib
    Mousavian, Zeinab
    Abbasi, Mehrnaz
    Samadi, Mehnoosh
    Pasdar, Yahya
    [J]. NUTRITION & FOOD SCIENCE, 2020, 50 (06): : 1279 - 1293
  • [5] Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial
    Seyed Ali Jazayeri-Tehrani
    Seyed Mahdi Rezayat
    Siavash Mansouri
    Mostafa Qorbani
    Seyed Moayed Alavian
    Milad Daneshi-Maskooni
    Mohammad-Javad Hosseinzadeh-Attar
    [J]. Nutrition & Metabolism, 16
  • [6] The effects of zinc supplementation on metabolic profile and oxidative stress in overweight/obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial
    Fathi, Mojdeh
    Alavinejad, Pezhman
    Haidari, Zahra
    Amani, Reza
    [J]. JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2020, 62
  • [7] The nanocurcumin reduces appetite in obese patients with non-alcoholic fatty liver disease (nafld): a double-blind randomized placebo-controlled clinical trial
    Jazayeri-Tehrani, Seyed Ali
    Rezayat, Seyed Mahdi
    Mansouri, Siavash
    Qorbani, Mostafa
    Alavian, Seyed Moayed
    Daneshi-Maskooni, Milad
    Hosseinzadeh-Attar, Mohammad-Javad
    [J]. NANOMEDICINE JOURNAL, 2018, 5 (02) : 67 - 76
  • [8] Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial
    Safarpour, Peivasteh
    Daneshi-Maskooni, Milad
    Vafa, Mohammadreza
    Nourbakhsh, Mitra
    Janani, Leila
    Maddah, Mohsen
    Amiri, Fatemeh-Sadat
    Mohammadi, Fereshteh
    Sadeghi, Homa
    [J]. BMC FAMILY PRACTICE, 2020, 21 (01)
  • [9] Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial
    Peivasteh Safarpour
    Milad Daneshi-Maskooni
    Mohammadreza Vafa
    Mitra Nourbakhsh
    Leila Janani
    Mohsen Maddah
    Fatemeh-Sadat Amiri
    Fereshteh Mohammadi
    Homa Sadeghi
    [J]. BMC Family Practice, 21
  • [10] Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial
    Naeini, Fatemeh
    Namkhah, Zahra
    Tutunchi, Helda
    Rezayat, Seyed Mahdi
    Mansouri, Siavash
    Jazayeri-Tehrani, Seyed Ali
    Yaseri, Mehdi
    Hosseinzadeh-Attar, Mohammad Javad
    [J]. TRIALS, 2021, 22 (01)